Fate Therapeutics
FATE
37 hedge funds and large institutions have $57.9M invested in Fate Therapeutics in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 6 closing their positions.
67.73% more ownership
Funds ownership: 0% → 67.73% (+68%)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $60.8M → $57.9M (-$2.9M)
8% less funds holding
Funds holding: 40 → 37 (-3)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$10.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$2.01M |
| 3 |
Morgan Stanley
New York
|
+$1.49M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$226K |
| 5 |
Renaissance Technologies
New York
|
+$58.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.84M |
| 2 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$908K |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$768K |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$568K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$149K |
FATE Hedge Fund Activity: Q4 2016 in Review
37 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2016, worth a combined $57.9M — down 4.8% from $60.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of FATE and 5 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 12 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $10.1M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $1.84M sold.
- 37 institutional investors held Fate Therapeutics (FATE) as of Q4 2016, down from 40 in Q3 2016.
- Funds reported $57.9M of Fate Therapeutics stock for Q4 2016, down 4.8% quarter-over-quarter.
- 5 funds opened new Fate Therapeutics positions in Q4 2016 and 6 closed out, a net change of -1 holder.
- The largest Fate Therapeutics buyer in Q4 2016 was BVF Inc, an estimated $10.1M added.
- The largest Fate Therapeutics seller in Q4 2016 was EcoR1 Capital, an estimated $1.84M sold.
Based on aggregated 13F filings for Q4 2016.